ISOFOL MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.718 SEK | +3.76% |
|
-2.84% | -1.64% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Companyâs main shareholders are Biofol AB and Yield Life Science AB.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -1.64% | 10.26M | |
| +4.16% | 70.78B | |
| +10.40% | 9.15B | |
| -17.03% | 4.84B | |
| +37.51% | 4.22B | |
| +3.92% | 3.92B | |
| +18.14% | 2.55B | |
| -24.13% | 2.26B | |
| -29.70% | 2.24B | |
| +9.09% | 1.92B |
- Stock Market
- Equities
- ISOFOL Stock
- News Isofol Medical AB
- Isofol Medical CEO To Depart In June 2023
